

Daftar Pustaka

1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620–9.
2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020;2019(February):16–24. Available from: <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>
3. Vargas M, Rojo C. Letter to the editor Ferritin levels and COVID-19. *Ther Adv Vaccines.* 2020;9(5):2019–20.
4. Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L. Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. *Int J Lab Hematol.* 2020;1–7.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–62. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
6. Liu T, Zhang J, Yang Y, Zhang L, Ma H, Li Z, et al. The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019. *SSRN Electron J.* 2020;2019.
7. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. *Ther Adv Respir Dis.* 2020;14:1–14.
8. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Heal.* 2020;25(3):278–80.
9. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. *PLoS Pathog.* 2020;16(8):e1008762. Available from: <http://dx.doi.org/10.1371/journal.ppat.1008762>
10. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *J Microbiol Immunol Infect.* 2020;0–4. Available from: <https://doi.org/10.1016/j.jmii.2020.03.022>
11. Burhan E, Isbaniah F, Susanto AD, Aditama TY, Soedarsono, Sartono TR, et al. Pneumonia COVID 19 Diagnosis & Penatalaksanaan di Indonesia. *Perhimpunan Dokter Paru Indonesia (PDPI).* 2020. 1-58 p.
12. Biswas TK, Biswas M, Bandyopadhyay R. An Overview of Coronavirus COVID-19 with their Pathogenesis and Risk Assessment of the Disease Utilizing Positive Predictive Value of the Clinical and Laboratory Data. *Trans Indian Natl Acad Eng.* 2020;5(2):417–27. Available from: <https://doi.org/10.1007/s41403-020-00147-1>
13. Wu Z. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China. *Jama.* 2020;
14. WHO. Novel Coronavirus (2019-nCoV). *WHO Bull.* 2020;(JANUARY):1–7. Available from: <https://www.who.int/china/news/detail/22-01-2020-field-visit-wuhan-china-jan-2020%0D>
15. World Health Organisation. Coronavirus disease 2019 (COVID-19) Situation Report – 42 Data as reported by 10 AM CET 02 March 2020 H. A

- A Pract. 2020;14(6):e01218.
16. Kemenkes RI. Situasi Terkini Perkembangan (COVID-19). Kemenkes. 2020;17–9. Available from: https://covid19.kemkes.go.id/download/Situasi_Terkini_050520.pdf
 17. Ahmad S. A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. *Eurasian J Med Oncol.* 2020;4(2):116–25.
 18. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res.* 2008;18(2):290–301.
 19. Bergmann CC, Silverman RH. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. *Cleve Clin J Med.* 2020;87(5):1–7.
 20. Wit E De, Doremalen N Van, Falzarano D, Munster VJ. REVIEWS SARS and MERS: recent insights into emerging coronaviruses. *Nat Publ Gr.* 2016;14:523–34.
 21. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020;10(2):102–8. Available from: <https://doi.org/10.1016/j.jpha.2020.03.001>
 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. *thelancet.* 2020;395:497–506.
 23. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *Lancet.* 2020;395(10224):e35–6. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30305-6](http://dx.doi.org/10.1016/S0140-6736(20)30305-6)
 24. World Health Organization (WHO). Q&A: similarities and differences – COVID-19 and influenza. *Newsroom/Q&A Detail.* 2020.
 25. World Health Organization (WHO). Clinical management of COVID-19. interim guidance. 2020 [cited 2020 Oct 25]. Available from: [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected).
 26. Li L quan, Huang T, Wang Y qing, Wang Z ping, Liang Y, Huang T bi, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol.* 2020;92(6):577–83.
 27. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res.* 2020;41(22):2124–5.
 28. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. 2020;(March):1–7.
 29. Kemenkes R. Pedoman Kesiapsiagaan Menghadapi Infeksi Novel Coronavirus (2019-nCov). Direktorat Jenderal Pencegah dan Pengendali Penyakit. 2020;(July):0–74.
 30. KemenkesRI. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). *MenKes/413/2020.* 2020;2019:1–207.
 31. Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit

- Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI). Pedoman Tatalaksana COVID-19. Pedoman Tatalaksana COVID-19. 2020. 3-6 p.
32. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. *Metallomics*. 2014;6(4):748–73.
 33. Arosio P, Ingrassia R, Cavadini P. Ferritins: A family of molecules for iron storage, antioxidation and more. *Biochim Biophys Acta - Gen Subj*. 2009;1790(7):589–99. Available from: <http://dx.doi.org/10.1016/j.bbagen.2008.09.004>
 34. Wang W, Knovich MA, Coffman LG, Torti FM, Torti S V. Serum ferritin: Past, present and future. *Biochim Biophys Acta - Gen Subj*. 2010;1800(8):760–9. Available from: <http://dx.doi.org/10.1016/j.bbagen.2010.03.011>
 35. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Med*. 2013;11(1).
 36. Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. *Immunol Res*. 2020;68(4):213–24.
 37. Kühn LC. Iron regulatory proteins and their role in controlling iron metabolism. *Metallomics*. 2015;7(2):232–43.
 38. Pastora JG, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? *Clin Chim Acta J*. 2020;509:249–51.
 39. Alunno A, Carubbi F, Rodríguez-carrio J. Storm, typhoon, cyclone or hurricane in patients with COVID-19 ? Beware of the same storm that has a different origin. *Rheum Musculoskelet Dis*. 2020;6:1–4.
 40. Dahan S, Segal G, Katz I, Hellou T, Tietel M, Bryk G, et al. Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation. *IMAJ*. 2020;22:1–22.
 41. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). *BMJ*. 2020;1–13.
 42. Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. *Inflamm Regen*. 2020;40(1).
 43. Hu Q, Hao C, Tang S. From sepsis to acute respiratory distress syndrome (ARDS): Emerging preventive strategies based on molecular and genetic researches. *Biosci Rep*. 2020;40(5):1–9.
 44. Edeas M, Saleh J, Peyssonnaud C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? *Int J Infect Dis*. 2020;97:303–5. Available from: <https://doi.org/10.1016/j.ijid.2020.05.110>
 45. Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. *J Infect*. 2020;81:647–79.

46. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934–43.
47. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med.* 2020;382(13):1199–207.
48. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Heal.* 2020;8(April):1–6.
49. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? *Clin Exp Pharmacol Physiol.* 2013;40(8):551–9.
50. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708–20.
51. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. *PLoS One.* 2020;15(6 June). Available from: <http://dx.doi.org/10.1371/journal.pone.0234765>
52. Paudel SS. A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities. *Res Sq.* 2020;1–16.
53. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, et al. Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis Kaochang. *Eur J Clin Microbiol Infect Dis.* 2020;
54. Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of Neutrophil-to-Lymphocyte is associated with severe COVID-19. *Epidemiol Infect.* 2020;1–6.
55. Lomoro P, Verde F, Zerboni F, Simonetti I, Borghi C, Fachinetti C, et al. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review. *Eur J Radiol Open.* 2020;7(April):100231. Available from: <https://doi.org/10.1016/j.ejro.2020.100231>
56. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507–13. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7)
57. Carcillo JA, Kernan KK, Horvat CM, Simon DW, Aneja RK. Why and How Is Hyperferritinemic Sepsis Different from Sepsis without Hyperferritinemia?*. *Pediatr Crit Care Med.* 2020;509–12.
58. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Lab Anal.* 2020;34(10):1–18.
59. Luo L, Fu M, Li Y, Hu S, Luo J, Chen Z, et al. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. *Clin Cardiol.* 2020;
60. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing

- Type 2 Diabetes. *Cell Metab.* 2020;31(6):1068–1077.e3. Available from: <https://doi.org/10.1016/j.cmet.2020.04.021>
61. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. *Crit Care.* 2020;24(1):2–5.
 62. Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe or critical type 2019 novel coronavirus pneumonia. *Lab Invest.* 2020;100(6):794–800. Available from: <http://dx.doi.org/10.1038/s41374-020-0431-6>
 63. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J Infect Dis.* 2020;95:304–7. Available from: <https://doi.org/10.1016/j.ijid.2020.04.061>
 64. Torti FM, Torti S V. Regulation of ferritin genes and protein. *Blood.* 2002;99(10):3505–16.
 65. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol.* 2017;29(9):401–9.